Aeglea BioTherapeutics, Inc. announced the appointment of Cameron Turtle, DPhil as Chief Executive Officer (CEO) and member of the Board of Directors. Prior to his appointment as CEO, Dr. Turtle was the Chief Operating Officer of Spyre and previously served as the Chief Strategy Officer of BridgeBio Pharma, Inc. and Chief Business Officer of Eidos Therapeutics, Inc.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
34.61 USD | +3.13% | +3.95% | +60.83% |
Apr. 19 | Sector Update: Health Care Stocks Steady Pre-Bell Friday | MT |
Apr. 19 | Spyre Therapeutics Files Mixed-Securities Shelf Registration for About 33.4 Million Shares | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+60.83% | 1.35B | |
-2.76% | 103B | |
+1.40% | 95.28B | |
+1.46% | 22.15B | |
-15.68% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.04% | 16.05B | |
+5.05% | 13.68B | |
+33.21% | 12.17B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Aeglea BioTherapeutics, Inc. Appoints Cameron Turtle as Chief Executive Officer